Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2021-03-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第三十二次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding a specific agenda item to be discussed at the company's board meeting. It references compliance with regulatory guidelines and company bylaws, and it is a pre-approval or endorsement related to a board meeting agenda item about a loan agreement and guarantee. The document is short (956 characters) and does not contain financial statements or detailed financial data. It is not a full report but rather a governance-related statement tied to board meeting procedures. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters.
2021-03-16 Chinese
《独立董事工作制度》
Governance Information Classification · 95% confidence The document is a detailed internal governance policy titled 'Independent Director Work System' for Zhuhai Sailong Pharmaceutical Co., Ltd. It outlines the roles, responsibilities, qualifications, nomination, election, powers, duties, and remuneration of independent directors. It references relevant laws and regulations but does not contain financial data, audit results, or financial statements. It is a governance-related document focused on board structure and director duties rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length (6551 characters) and content confirm it is a full governance policy, not a brief announcement or certification.
2021-03-16 Chinese
公司章程修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程) reflecting changes such as capital increase, shareholding rules, board member qualifications, and other governance-related provisions. It includes specific legal references and detailed clauses about shareholder rights, board responsibilities, and share transactions. The document is not a financial report, earnings release, or announcement of voting results. It is a governance-related document outlining internal company rules and structure. Therefore, it fits the category of Governance Information (CGR). The document length (6364 characters) and content confirm it is the actual governance document, not just an announcement or summary.
2021-03-16 Chinese
《内幕信息知情人管理制度》
Governance Information Classification · 95% confidence The document is a detailed internal management system for insiders aware of material non-public information at Zhuhai Sailong Pharmaceutical Co., Ltd. It outlines definitions, scope, responsibilities, confidentiality, and reporting requirements related to insider information. It references regulatory laws and stock exchange rules, and includes an insider information registration form. There are no financial statements, earnings data, or report summaries. It is a governance and compliance document focused on insider information management and disclosure controls, not a financial report or announcement. Therefore, it fits best under Governance Information (CGR).
2021-03-16 Chinese
《董事、监事及高级管理人员持有本公司股份及其变动管理制度》
Governance Information Classification · 95% confidence The document is a detailed internal management system regarding the holding and trading of company shares by directors, supervisors, and senior management personnel of Zhuhai Sailong Pharmaceutical Co., Ltd. It outlines rules, reporting requirements, restrictions, and legal responsibilities related to insider share transactions. The content focuses on governance and compliance with securities laws and stock exchange regulations, specifically about insider shareholding and trading restrictions. There is no indication that this is a financial report, earnings release, or announcement of voting results. It is not a proxy statement or remuneration report. The document is a governance-related policy document detailing internal rules and procedures for managing insider shareholdings and transactions. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6161 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2021-03-16 Chinese
珠海赛隆药业股份有限公司独立董事候选人声明（陈小辛）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Zhuhai Sailong Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, compliance with laws and regulations, and independence criteria. There is no financial data, no mention of financial results, no report publication, or voting results. The content is focused on the candidate's eligibility and compliance for a board position, which aligns with announcements related to board or management information, specifically about director candidacy. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length and detail support this classification with high confidence.
2021-03-16 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.